A Phase 3 interventional study of Lactobacillus brevis CD2 Lozenges in Chronic Periodontitis, sponsored by Next Gen Pharma India Pvt. Ltd.. Completed at 1 site in India. Open to participants aged 30 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-01-10.
Sponsored by Next Gen Pharma India Pvt. Ltd. · Phase 3, Interventional, and Treatment
Periodontitis is one of the most common chronic inflammatory disease with the etiology of bacterial plaque and is associated with a number of putative bacterial species. The periodontal destruction is substantially mediated by the host, driven by the bacterial challenge. The presence of pathogenic bacteria with the absence of so-called "beneficial bacteria" and the susceptibility of the host are the main aetiological factors of periodontal diseases.
386 studies on the registry are indexed under Chronic Periodontitis; 23 are open to participants now.
This study's enrollment of 60 is above the median of 46 across 314 interventional studies indexed under Chronic Periodontitis.
Browse Chronic Periodontitis studies →Next Gen Pharma India Pvt. Ltd. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
30 chronic periodontitis patients, having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks
Drug: Lactobacillus brevis CD2 Lozenges
30 chronic periodontitis patients, not having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks
Drug: Lactobacillus brevis CD2 Lozenges
Each lozenge contains not less than 1 billion Colony forming unit of Lactobacillus brevis CD2
Also known as: Probiotics
Improvement in Clinical Periodontal Indices
Improvement in clinical periodontal indices, namely, Plaque Index (PI), Gingival Index (GI), Probing Pocket Depth (PPD)
Time frame: 8 weeks
Change in microbiological indices
Porphyromonas gingivalis, Tanerella forsythus
Time frame: 8 weeks
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Next Gen Pharma India Pvt. Ltd.